Galenica Ltd.

Latest Results (19.07.2026):

Summary — Galenica Ltd., Q4 2025 (reporting full-year 2025): Galenica Ltd. posted a strong full-year 2025 result in its Annual Report 2025. Consolidated net sales rose 5.5% to CHF 4,135.6 million and adjusted EBIT increased 11.3% to CHF 234.8 million. Adjusted net profit from continuing operations was CHF 188.7 million (+3.0%). The Board will propose a higher dividend of CHF 2.50 per share (+8.7%). The group completed the strategic acquisition of diagnostics provider Labor Team in September 2025, expanded its pharmacy network to 381 outlets, and reiterated growth guidance for 2026.

Top-line and profitability

Net sales: CHF 4,135.6m (+5.5% vs 2024). Adjusted EBIT: CHF 234.8m (+11.3%). Reported EBIT was CHF 232.4m (+8.4%). Adjusted profit from continuing operations: CHF 188.7m (+3.0%). Management attributes growth to broad contributions across Products & Care and Logistics & IT and to special factors of CHF 6.2m impacting EBIT.

Dividend and capital markets

The Board proposes a gross dividend of CHF 2.50 per share (up 8.7%). Share price at year-end: CHF 97.70. Adjusted earnings per share: CHF 3.76; reported EPS: CHF 3.67. Market capitalisation at year-end: CHF 4,867.8m.

Strategic M&A and scope expansion

Galenica Ltd. acquired Labor Team Group (diagnostics) in September 2025, marking entry into diagnostics and contributing about 1% to Group sales growth. The group also increased its online/retail footprint with investments including a majority stake in Puravita (Dec 2025) and pilot of a new Amavita pharmacy concept.

Pharmacies and healthcare services

The network grew to 381 pharmacies. Fee-based healthcare services rose ~29% to 368,000 (including ~93,000 vaccinations), reflecting stronger demand for consultations and basic care and continued positioning of pharmacies as first points of contact.

Operational improvements and digitalisation

Key operational items: ERP modernisation at Galexis (Lausanne‑Ecublens) and Alloga’s completed SAP rollout (2024) drove efficiency gains (Alloga reported ~20% efficiency improvement). HCI/Documedis registered 553 million clinical decision support checks (+50%). Medifilm expanded blister-packaging capacity.

Segment performance

Products & Care net sales CHF 1,816.4m (+6.8%); adjusted EBIT for the segment CHF 175.2m (+9.4%). Logistics & IT net sales CHF 3,332.6m (+4.8%); adjusted EBIT CHF 61.7m (+14.8%). All business areas contributed to growth.

Balance sheet and cash flow

Total assets: CHF 3,297.1m (+7.4%). Shareholders’ equity decreased to CHF 1,485.0m (–4.3%). Adjusted net debt rose to CHF 674.8m (from CHF 424.1m) and adjusted gearing increased; free cash flow was negative CHF –87.4m (versus CHF 61.0m prior year).

Outlook for 2026

Galenica Ltd. expects revenue growth of 5–7% for 2026 and an increase in adjusted EBIT of 6–8% (or 9–11% excluding the CHF 6.2m one‑off items from 2025). Continued focus areas are customer-centric pharmacy services, diagnostics integration, digitalisation and efficiency improvements.